Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05257356
Other study ID # P000PS_203872/1
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date April 6, 2022
Est. completion date May 31, 2024

Study information

Verified date February 2024
Source Balgrist University Hospital
Contact Susanne Becker, Dr. Prof.
Phone +41 44 510 73 52
Email susanne.becker@balgrist.ch
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Chronic pain causes immense suffering and reductions in quality of life as well as enormous socioeconomic costs. Very many chronic pain patients fall into the category of unspecific pain, i.e. pain without clear medical explanation, with lacking effective treatments. It is assumed that a negative hedonic shift, characterized by excessive emotional-motivational processing and neg-ative affect, contributes causally to the development and maintenance of chronic pain. The mechanisms leading to such a shift are largely unclear; however, learning mechanisms appear likely candidates, possibly causing decreased connectivity in the fronto-striatal brain circuits. The project's over-all aim is to characterize mechanisms of emotional-motivational pain pro-cessing. The specific objectives are to illustrate that emotional-motivational pain components are heightened in chronic pain and that they can be de-creased by counterconditioning as an important and pervasive mechanisms in everyday life. Furthermore, its neural correlates in fronto-striatal networks underlying the conditioning effects will be characterized.


Description:

Chronic pain is a major personal and societal problem causing immense suffering and reductions in quality of life as well as enormous socioeconomic costs (e.g. estimated as 11.2 Mio CHF of direct and indirect costs for chronic back pain in Switzerland in 2011. 90% of the chronic back pain patients fall into the category of unspecific pain, i.e. pain without clear medical explanation described as chronic primary pain in the new International Classification of Diseases ICD-11 (World Health Organization). This lack of medical explanation severely hampers diagnostic procedures and effective treatments. For such unspecific pain, strong influences of emotional and cognitive factors are known. However, the majority of pain research focuses on molecular and neuronal mechanisms of nociception (i.e. the neural encoding and processing of actually or potentially tissue-damaging events) without relating such processes to the subjective experience of and suffering from pain and modulatory psychological emotional-motivational influences. Considering the large category of unspecific pain and the fact that effective treatment is lacking, more research following a mechanism-oriented framework focusing on emotional-motivational pain components and related psychological mechanisms is needed, as done here. The perception of pain is multidimensional: The International Association for the Study of Pain (IASP) defines pain as "an unpleasant sensory and emotional experience associated with actual or potential tissue damage, or described in terms of such damage", highlighting the crucial point that pain always comprises emotional components. Specifically, pain comprises sensory-discriminative, emotional-motivational and cognitive-evaluative components as initially proposed in Melzack's tripartite model of pain. Typically, the sensory-discriminative and emotional-motivational components are well aligned; but these components can dissociate. For example, many people find a painful massage pleasant or enjoy eating hot chilies, likely through a reappraisal of the painful sensation. Extreme examples are prefrontal lobotomy, cingulotomy or strong morphine analgesia where pain is still recognized in its sensory-discriminative dimension, but loses its aversiveness and threat. Such a loss of emotional-motivational pain components can lead to severe injuries and life-threatening conditions. Although these examples affect only very few people, they illustrate a conceptually important point: Emotional-motivational aspects are the driving force in pain. The dissociation of pain components: As described above and as an idea inherent to Melzack's tripartite model of pain, the different pain components can dissociate. The underlying mechanisms how such a dissociation can develop and be maintained are largely unclear. Based on earlier findings, operant and associative learning mechanisms appear to be likely candidates. Applying the mechanisms of associative conditioning, a counterconditioning experiment showed impressively a dissociation between sensory-discriminative and emotional-motivational pain components. Counterconditioning is a specific form of classical conditioning used to reduce negative stimulus valence through a new association between a behavior and a stimulus of an oppositive valence. For example, Eroféeva applied this principle in the context of pain, pairing a positive stimulus (food) with an aversive painful stimulus in dogs. The appetitive response to the positive stimulus gradually and completely replaced aversive pain responses, suggesting that the pain lost its aversiveness, thus diminishing its emotional-motivational component. However, since the dogs still utilized the painful stimulus to predict the rewarding stimulus, sensory-discriminative pain components must have been preserved. This example illustrates that learning might be a mechanism underlying a gradual dissociation of sensory-discriminative and emotional-motivational pain components. The negative hedonic shift in chronic pain: In line with the observation that learning related to a dissociation of different pain components can be altered, emotional-motivational components appear to dominate over sensory-discriminative components in chronic pain. For example, the influential Fear-Avoid-ance Model of Pain termed chronic pain as "exaggerated pain perception" in its earliest version, because of disproportionally augmented emotional-motivational relative to sensory-discriminative pain components. Such increased emotional-motivational pain perception is often reflected in chronic pain patients in heightened pain aversiveness and pain avoidance behavior. Further and in line with such increases, recent findings suggest that pain processing is characterized by a functional shift from nociceptive to non-nociceptive emotional brain circuits in chronic pain, specifically to fronto-striatal circuits. Such a shift in chronic pain fits the observation of augmented negative affect and impaired motivated behavior, mirrored in anhedonia (i.e. the inability to feel pleasure) and very high comorbidity (up to 86%) between chronic pain and affective disturbances. Based on such observations, chronic pain has been described to induce a negative hedonic shift. Although this suggestion has been cited often and is compelling in explaining the development and maintenance of unspecific chronic pain, the underlying mechanisms of such a shift have not directly been investigated so far. It has been shown that patients with constant chronic back pain have increased activation in the medial prefrontal cortex (mPFC) and in the amygdala, as well as an increased incidence of white matter and increased functional connections between the mPFC, the nucleus accumbens (NAcc) and the amygdala compared to recovered patients and healthy controls. Of particular importance, altered fronto-striatal circuits, especially the increased functional connectivity between the NAcc and ventromedial prefrontal cortex (vmPFC), predicts the transition from subacute to chronic pain. Moreover, the importance of the NAcc-vmPFC connectivity for the modulation of pain perception has been confirmed in healthy persons. The aims of this study are therefore (1) to illustrate that emotional-motivational components are in-creased relative to sensory-discriminative components in chronic pain, (2) to show that increased emo-tional motivational pain responses in chronic pain can also be decreased by counterconditioning, leading to a normalization of pain perception relative to healthy individuals as well, and (3) to assess the neural correlate of the counterconditioning effects on emotional-motivational pain responses, specifically alterations in functional connectivity yin fronto-striatal networks. Intended intervention: All participants perform one psychophysical task to assess sensory-discriminative and emotional-motivational pain responses simultaneously. In Substudy 1 an associative learning paradigm will be implemented to dissociating the sensory-discriminative pain responses compared to emotional-motivational pain responses by monetary reinforcement. In Substudy 2, the effects of the counterconditioning on fronto-striatal networks will be assessed by MRI. Potential for new scientific generalizable knowledge: Our knowledge on the basic mechanisms of pain increased rapidly in recent years. Nevertheless, treatment of chronic pain is surprisingly unsuc-cessful. Particularly, patients suffering from unspecific pain often do not get efficient treatment. This gap between basic knowledge and applied treatment likely is caused by a mismatch between research foci and the subjective complains of patients. Basic research focuses on neurobiological basic mechanisms, e.g. on molecular and neuronal levels. Although indisputable of high relevance for our understanding of pian, it is hard to transfer these basic mechanisms directly to the multifaceted experience of pain in humans, because this can be strongly modulated by emotional and cognitive processes. The goal of this study is to provide a substantial contribution to lose this gap by (1) providing new methods needed for an appropriate investigation of the problem outlined and (2) by gathering new knowledge on pain mechanisms relevant in the development and maintenance of chronic pain. This study is a Clinical Study Category A because it includes an intervention that is neither a drug nor a transplant. The risk for the participants is minimal.


Recruitment information / eligibility

Status Recruiting
Enrollment 170
Est. completion date May 31, 2024
Est. primary completion date May 31, 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 70 Years
Eligibility HEALTHY PARTICIPANTS Inclusion criteria: - Between 18 and 70 years of age (in Substudy 1: age- and sex-matched to chronic pain patients) - Good overall health status - Sufficient knowledge of German or English to follow instructions - Ability to give written informed consent Exclusion criteria: - Pain longer than >3 consecutive days and on more than 30 days within the last 12 months - Major psychiatric or neurological disorders, and substance abuse - Consumption of alcohol, illegal drugs, and analgesic drugs within 24 hours before testing - Pregnancy - For Substudy 2: An MR-specific safety questionnaire will be filled in to check for any contradiction to magnetic resonance imaging (MRI): wearing an electronic device, implants or prosthetics, injury from metal parts or fragments, metal parts in or on the body, surgery on the head, heart or back, tattoo or permanent makeup, problems lying still for long periods of time, claustrophobia, possible pregnancy, metal contraceptive coil CHRONIC PAIN PATIENTS Inclusion criteria: - Between 18 and 70 years of age - Unspecific musculoskeletal pain as defined according to the ICD-11 as chronic primary pain (MG30.1, e.g. chronic widespread pain, complex regional pain syndrome, chronic primary headache or orofacial pain, chronic migraine, chronic tension-type headache, trigeminal autonomic cephalalgias, burning mouth syndrome, chronic primary visceral pain, irritable bowel syndrome, chronic primary musculoskeletal pain), and which is not classified as chronic cancer related pain (MG30.2; e.g. chronic cancer pain, chronic post-cancer treatment pain), chronic postsurgical or post traumatic pain (MG30.3; e.g. chronic postsurgical pain, chronic posttraumatic pain), chronic secondary musculoskeletal pain (MG30.4; e.g. chronic musculoskeletal pain from persistent inflammation, chronic musculoskeletal pain associated with structural changes, chronic musculoskeletal pain associated with a disease of the nervous system), chronic secondary visceral pain (MG30.5; e.g. chronic visceral pain from persistent inflammation, chronic visceral pain from vascular mechanisms, chronic visceral pain from mechanical factors), chronic neuropathic pain (MG30.6; e.g. chronic peripheral neuropathic pain, trigeminal neuralgia, postherpetic neuralgia, chronic central neuropathic pain), chronic secondary headache or orofacial pain (MG30.7; e.g. chronic dental pain, chronic neuropathic orofacial pain, trigeminal neuralgia, headache or orofacial pain attributed to chronic secondary temporo-mandibular disorders), other specified chronic pain (MG30.Y), or other non-specified chronic pain (MG30.Z) - Sufficient knowledge of German or English to follow instructions - Ability to give written informed consent Exclusion criteria: - Major psychiatric or neurological disorders, and substance abuse - Regular intake of opioids for pain (e.g. burprenorphine, codeine, fentanyl, hydromorphone, orphine, oxycodone, tapentadol, tilidine/na-loxone, tramadol) - Consumption of alcohol, illegal drugs, and analgesic drugs within 24 hours before testing - Pregnancy

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
psychophysical tasks
Substudy 1(b): All participants will perform one psychophysical task to assess sensory-discriminative and emotional-motivational pain responses simultaneously. The responses and the reaction times of chronic pain patients will be compared to those of healthy participants to characterize possible alterations in the patients (Substudy 1). Associative learning by monetary reinforcement will be implemented to diminish the aversiveness of the pain, which is assumed to be already increased in the patients. Substudy 2: As in Substudy 1, all participants will perform one psychophysical task to assess sensory-discriminative and emotional-motivational pain responses simultaneously combined with MRI assessing the effects of the counterconditioning on fronto-striatal circuits.

Locations

Country Name City State
Switzerland Balgrist Campus Zürich

Sponsors (2)

Lead Sponsor Collaborator
susanne becker SNSF

Country where clinical trial is conducted

Switzerland, 

Outcome

Type Measure Description Time frame Safety issue
Primary Successful Avoidance Responses In Substudy1(b) and Substudy2: The number of successful avoidance responses upon correct discrimination responses in the task assessing sensory-discriminative and emotional-motivational pain responses simultaneously. during the procedure
Primary Fronto-striatal Networks In Substudy 2: Blood oxygen level dependent (BOLD) signal and changes in functional connectivity in fronto-striatal networks while assessing sesnorydiscriminative and emotional-motivational pain responses simultaneously. during the procedure
Secondary Reaction Times (RT) reaction times (RT) in the trials of the psychophysical task during the procedure
Secondary Pain Threshold in °C individual pain threshold assessed with experimental heat pain by the methods of limits baseline
Secondary Pain Tolerance in °C individual pain tolerance assessed with experimental heat pain by the methods of limits baseline
Secondary Visual Analogue Scale (VAS) for Perceived Pain Intensity self-reported perceived pain intensity assessed with experimental heat pain rated on a visual analogue scale (VAS) from 0 (no sensation) to 100 (pain threshold) and 200 (most intense pain tolerable) during the procedure
Secondary Visual Analogue Scale (VAS) for Perceived Pain Unpleasantness self-reported perceived pain unpleasantness assessed with experimental heat pain rated on a visual analogue scale from -100 (extremely unpleasant) to 0 (neutral) and +100 (extremely pleasant). during the procedure
Secondary Fear of Pain Questionnaire (FPQ-III) Score assessing pain-related fear; rating 30 items on a five-point Likert scale from 1 = "not afraid at all" to 5 = "extremely afraid" during the procedure
Secondary Fear-Avoidance Beliefs Questionnaire (FABQ) Score assessing fear of pain and the resulting avoidance of physical activity or work; rating 16 items on a seven-point Likert scale from 0 = "completely disagree" to 5 = "completely agree" during the procedure
Secondary Pain Catastrophizing Scale (PCS) Score assessing thoughts and feelings when experiencing pain (catastrophizing); rating 13 items on a five-point Likert scale from 0 = "not at all" to 4 = "all the time" during the procedure
Secondary Need Inventory of Sensation Seeking (NISS) Score assessing sensation seeking as a motivational trait; rating 17 items on a five-point Likert scale from 1 = "almost never" to 5 = "almost always" during the procedure
Secondary Revised Life-Orientation Test (LOT-R) Score assessing dispositional optimism; rating 10 items on a five-point Likert scale from 0 = "strongly disagree" to 4 = "strongly agree" during the procedure
Secondary Snaith-Hamilton Pleasure Scale (SHAPS) Score assessing individual hedonic capacity; rating 14 items with a set of 4 response categories "definitely agree", "agree", "disagree" and "strongly disagree", with either of the agree responses receiving a score of 0, and with either of the disagree responses receiving a score of 1 during the procedure
Secondary Short Form of the Barratt Impulsiveness Scale (BIS-15) Score assessing the personality trait of impulsivity; rating 5 items on a four-point Likert scale from 1 = "rarely / never" to 5 = "almost always / always" during the procedure
Secondary West Haven-Yale Multidimensional Pain Inventory (WHYMPI) Score assessing clinical pain and pain chronicity; rating 20 items with a set of 7 response categories (scores from 0 to 6), with higher values indicating higher clinical pain and pain chronicity during the procedure
Secondary Autonomic Reactions: Electrocardiography (ECG) assessing changes in the heart rate via electrocardiography (ECG) as an indicator of sympathetic activities in response to the pain stimuli and task performance during the procedure
Secondary Autonomic Reactions: Galvanic Skin Response (GSR) assessing changes in the skin conductance with via Galvanic Skin Response (GSR) as an indicator of sympathetic activities in response to the pain stimuli and task performance during the procedure
See also
  Status Clinical Trial Phase
Completed NCT01659073 - Using Perfusion MRI to Measure the Dynamic Changes in Neural Activation Associated With Caloric Vestibular Stimulation N/A
Recruiting NCT05914311 - Use of Dermabond in Mitigation of Spinal Cord Stimulation (SCS) Trial Lead Migration N/A
Recruiting NCT05422456 - The Turkish Version of Functional Disability Inventory
Enrolling by invitation NCT05422443 - The Turkish Version of Pain Coping Questionnaire
Completed NCT05057988 - Virtual Empowered Relief for Chronic Pain N/A
Completed NCT04385030 - Neurostimulation and Mirror Therapy in Traumatic Brachial Plexus Injury N/A
Recruiting NCT06206252 - Can Medical Cannabis Affect Opioid Use?
Completed NCT05103319 - Simultaneous Application of Ketamine and Lidocaine During an Ambulatory Infusion Therapy as a Treatment Option in Refractory Chronic Pain Conditions
Completed NCT03687762 - Back on Track to Healthy Living Study N/A
Completed NCT04171336 - Animal-assisted Therapy for Children and Adolescents With Chronic Pain N/A
Completed NCT03179475 - Targin® for Chronic Pain Management in Patients With Spinal Cord Injury Phase 4
Completed NCT03418129 - Neuromodulatory Treatments for Pain Management in TBI N/A
Completed NCT03268551 - MEMO-Medical Marijuana and Opioids Study
Recruiting NCT06060028 - The Power of Touch. Non-Invasive C-Tactile Stimulation for Chronic Osteoarthritis Pain N/A
Recruiting NCT06204627 - TDCS* and Laterality Trainnning in Patients With Chronic Neck Pain N/A
Completed NCT05496205 - A SAD Study to Evaluate the Safety, Tolerability and PK/PD of iN1011-N17 in Healthy Volunteers Phase 1
Completed NCT00983385 - Evaluation of Effectiveness and Tolerability of Tapentadol Hydrochloride in Subjects With Severe Chronic Low Back Pain Taking Either WHO Step I or Step II Analgesics or no Regular Analgesics Phase 3
Recruiting NCT05118204 - Randomized Trial of Buprenorphine Microdose Inductions During Hospitalization Phase 4
Terminated NCT03538444 - Repetitive Transcranial Magnetic Stimulation for Opiate Use Disorder N/A
Not yet recruiting NCT05812703 - Biometrics and Self-reported Health Changes in Adults Receiving Behavioral Treatments for Chronic Pain